Last reviewed · How we verify
CP-690,550
CP-690,550 is a JAK inhibitor Small molecule drug developed by Pfizer. It is currently FDA-approved for Rheumatoid arthritis, Ulcerative colitis, Polyarticular course juvenile idiopathic arthritis. Also known as: tofacitinib, Tofacitinib, Double-blind, placebo-controlled period, Double-blind, Active Extension Period.
CP-690,550 (tofacitinib) is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation.
CP-690,550 (tofacitinib) is a JAK inhibitor that blocks Janus kinase signaling to reduce inflammatory cytokine production and immune cell activation. Used for Rheumatoid arthritis, Ulcerative colitis, Polyarticular course juvenile idiopathic arthritis.
At a glance
| Generic name | CP-690,550 |
|---|---|
| Also known as | tofacitinib, Tofacitinib, Double-blind, placebo-controlled period, Double-blind, Active Extension Period, double-blind, extension phase |
| Sponsor | Pfizer |
| Drug class | JAK inhibitor |
| Target | JAK1, JAK3 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Tofacitinib selectively inhibits JAK1 and JAK3, key enzymes in the intracellular signaling pathway downstream of cytokine receptors. By blocking JAK-STAT signaling, it suppresses the production of pro-inflammatory cytokines and reduces T-cell proliferation, thereby dampening the immune response in autoimmune and inflammatory conditions.
Approved indications
- Rheumatoid arthritis
- Ulcerative colitis
- Polyarticular course juvenile idiopathic arthritis
- Psoriasis
- Atopic dermatitis
Common side effects
- Upper respiratory tract infection
- Diarrhea
- Headache
- Elevated cholesterol
- Increased creatinine
- Serious infections
Key clinical trials
- A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA (PHASE3)
- CP-690-550 Ointment For Chronic Plaque Psoriasis (PHASE2)
- CP-690,550 Thorough QTc Study (PHASE1)
- A Study Evaluating The Efficacy And Safety Of CP-690,550 In Asian Subjects With Moderate To Severe Plaque Psoriasis (PHASE3)
- A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative Colitis (PHASE3)
- A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis (PHASE3)
- A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis (PHASE3)
- Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CP-690,550 CI brief — competitive landscape report
- CP-690,550 updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about CP-690,550
What is CP-690,550?
How does CP-690,550 work?
What is CP-690,550 used for?
Who makes CP-690,550?
Is CP-690,550 also known as anything else?
What drug class is CP-690,550 in?
What development phase is CP-690,550 in?
What are the side effects of CP-690,550?
What does CP-690,550 target?
Related
- Drug class: All JAK inhibitor drugs
- Target: All drugs targeting JAK1, JAK3
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Rheumatoid arthritis
- Indication: Drugs for Ulcerative colitis
- Indication: Drugs for Polyarticular course juvenile idiopathic arthritis
- Also known as: tofacitinib, Tofacitinib, Double-blind, placebo-controlled period, Double-blind, Active Extension Period, double-blind, extension phase
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing